CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM...
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a...
Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a...
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize...
Financing was led by New Enterprise Associates (NEA) and closed with additional new investor Atlas Venture and continued investment by...
Toronto, Ontario--(Newsfile Corp. - January 9, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a...
NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
HeartRisk™ Empowers Employers Who Adopt Cardio Diagnostics’ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business RisksCHICAGO--(BUSINESS...
This is the second CPT PLA code the American Medical Association (AMA) granted for the Company’s AI-powered coronary heart disease...
Obtaining a CPT PLA code marks a key milestone in securing reimbursement from federal and private payers for, and expanding...
-- SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive...
Atherosclerosis, an inflammatory disease characterized by buildup of cholesterol, lipids, and other substances (plaque) in arteries leading to heart attack...
CPT codes are critical to receiving reimbursement from federal and private payersCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader...
PMcardio Queen of Hearts PMcardio's Queen of Hearts AI model is the first certified solution to outperform doctors in heart...
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of...
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated...
Investment will drive commercialization and expansion of AI-powered non-invasive diagnostic tools to help evaluate cardiovascular riskBOSTON--(BUSINESS WIRE)--Elucid, a leading medical...
Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving...
CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, and Family Medicine Specialists...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual...